Please assess the completion status of the following clinical trial:

Trial Title: Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~* Men or women age 18 years or older~* Histologically or cytologically confirmed NSCLC~  * Recurrent, locally advanced or metastatic, inoperable NSCLC (Stage IIIB/IV)~ * Patients with Stage IIIB NSCLC must have a cytologically documented pleural effusion~* Failed or relapsed after receiving a platinum-containing chemotherapy regimen as first-line therapy for advanced NSCLC~* Measurable disease on computerized tomography (CT) scan~* ECOG Performance Status of 0 or 1~* Expected survival ≥12 weeks~* Provide written informed consent~EXCLUSION CRITERIA:~* More than 2 prior chemotherapy regimens~* Clinically significant laboratory abnormalities, specifically:~  * Total bilirubin ≥ institutional upper limit of normal (ULN)~ * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 x ULN concomitant with alkaline phosphatase \>2.5 x ULN~ * Serum creatinine ≥2.0mg/dL~ * Absolute neutrophil count \<1500/μL or platelets \<100,000/μL~* Untreated or symptomatic brain metastases~* Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix~* A history of severe hypersensitivity to drugs formulated with polysorbate 80~* Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol~* Patients who are within 28 days of chemotherapy, radiation therapy, immunotherapy, or other investigational medication for NSCLC.~* Pregnancy or lactation. Women of childbearing potential and non-vasectomized men must agree to use a barrier method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).